SystImmune, Inc., a clinical-stage biotechnology company, has dosed the first patient in the IZABRIGHT-Breast01 study, a global Phase 2/3 registrational study of izalontamab brengitecan (iza-bren) in triple negative breast cancer. This milestone triggers a one-time payment of $250 million by Bristol Myers Squibb, under the companies collaboration and license agreement.  SystImmune is eligible to receive up to an additional $250 million in contingent near-term payments and additional payments ...